What are the key drivers behind Vertex's revenue growth in this period?

Vertex's revenue growth is primarily driven by its net product revenues, which saw a significant increase of 25% year-over-year in the second quarter of 2019. This growth is largely attributed to the strong performance and uptake of SYMDEKO/SYMKEVI, following its approval in 2018, and continued contributions from ORKAMBI and KALYDECO. The ongoing expansion of patient eligibility through label enhancements and new reimbursement agreements also contributes to this growth.

What is the significance of the triple combination regimen and its regulatory status?

Vertex submitted a New Drug Application (NDA) to the FDA in July 2019 for its triple combination regimen of elexacaftor, tezacaftor, and ivacaftor. If approved, this regimen has the potential to significantly expand the number of cystic fibrosis patients eligible for Vertex's therapies and offer an improved treatment option for a majority of current patients. This represents a key strategic development for the company's core cystic fibrosis franchise.

How is Vertex investing in its future pipeline and expanding its therapeutic areas?

Vertex is actively investing in its future pipeline through research and development initiatives and strategic business development activities. This includes significant upfront payments for new collaborations, such as with Kymera Therapeutics, and the recent acquisition of Exonics Therapeutics. These actions are aimed at advancing therapies for cystic fibrosis and expanding into other serious diseases, including alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, and gene-editing therapies for neuromuscular disorders like Duchenne muscular dystrophy.

What is Vertex's current financial position and liquidity?

Vertex maintains a strong financial position, with cash, cash equivalents, and marketable securities totaling approximately $3.95 billion as of June 30, 2019. This increase from the prior year reflects strong operational cash flows and prudent financial management. The company's liquidity is considered sufficient to fund its operations and strategic initiatives for at least the next twelve months, providing flexibility for ongoing R&D, potential regulatory approvals, and business development activities.

VRTX 10-Q Quarterly Report Q2 FY2019 — Revenue, Net Income, EPS

Summary

Vertex Pharmaceuticals Inc. reported robust financial performance for the period ending June 30, 2019, with total revenues reaching $941.3 million for the quarter and $1.8 billion for the six-month period, representing significant year-over-year growth. This strong revenue performance was primarily driven by a substantial increase in net product revenues, particularly from the SYMDEKO/SYMKEVI drug. The company also demonstrated solid profitability, with net income attributable to Vertex rising to $267.4 million for the quarter and $536.1 million for the six-month period. Research and development expenses saw an increase, reflecting ongoing investments in pipeline expansion, including significant upfront payments for new collaborations and the acquisition of Exonics Therapeutics. Management anticipates continued revenue growth and has substantial liquidity, with cash, cash equivalents, and marketable securities totaling $3.95 billion, positioning the company well for future operational needs and strategic initiatives.

Financial Highlights

49 data points

Beta

Revenue

$941.29M

0.9% Gross Margin

Net Income

$267.43M

0.3% Net Margin

EPS (Diluted)

$1.03

Total Assets

$7.03B

Cash & Equivalents

$3.29B

Free Cash Flow

$447.39M

Financial Statements

Beta

Revenue	$941.29M
Cost of Revenue	$135.74M
Gross Profit	$805.55M
R&D Expenses	$379.09M
SG&A Expenses	$156.50M
Operating Expenses	$671.33M
Operating Income	$269.96M
Interest Expense	$14.84M
Net Income	$267.43M
EPS (Basic)	$1.04
EPS (Diluted)	$1.03
Shares Outstanding (Basic)	256.15M
Shares Outstanding (Diluted)	259.82M

Key Highlights

1Total revenues increased by 25% year-over-year to $941.3 million for Q2 2019 and by 29% to $1.8 billion for the first six months of 2019.
2Net income attributable to Vertex grew by 29% to $267.4 million for Q2 2019 and by 28% to $536.1 million for the first six months of 2019.
3Product revenues, driven by SYMDEKO/SYMKEVI, increased by 25% to $940.4 million in Q2 2019 and by 30% to $1.8 billion in the first six months of 2019.
4Research and development expenses increased by 12% in Q2 2019, partly due to a $50 million upfront payment to Kymera Therapeutics.
5The company submitted an NDA to the FDA for its triple combination regimen of elexacaftor, tezacaftor, and ivacaftor in July 2019.
6Vertex acquired Exonics Therapeutics in July 2019 for approximately $245 million, further expanding its gene-editing capabilities.
7Cash, cash equivalents, and marketable securities increased by 25% to $3.95 billion as of June 30, 2019.

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q2 Ended Jun 30, 2019

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions